[1] Zhu Z X,Huang J W,Liao M H,et al.Treatment strategy for hepatocellular carcinoma in China:radiofrequency ablation versus liver resection. Jpn J Clin Oncol,2016,46(12):1075-1080.
[2] Chen W,Zheng R,Baade P D,et al.Cancer statistics in China,2015. CA Cancer J Clin,2016,66(2):115-132.
[3] 余红星,陈颖,刘自鹏,等. 超声引导下经皮射频消融与激光消融治疗微小肝癌患者疗效初步比较研究. 实用肝脏病杂志,2017,20(3):320-323.
[4] 王鹤,董家鸿,卢实春,等. 手术切除与射频消融治疗原发性肝癌患者预后比较. 实用肝脏病杂志,2017,20(3):337-340.
[5] Roxburgh P,Evans T R.Systemic therapy of hepatocellular carcinoma:are we making progress. Adv Ther,2008,25(11):1089-1104.
[6] Yang J,Croniger CM,Lekstrom-Himes J,et al.Metabolic response of mice to a postnatal ablation of CCAAT/enhancer-binding protein alpha. J Biol Chem,2005,280(46):38689-38699.
[7] Wang N D,Finegold M J,Bradley A,et al.Impaired energy homeostasis in C/EBP alpha knockout mice. Science,1995,269(5227):1108-1112.
[8] Gery S,Tanosaki S,Bose S,et al.Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. Clin Cancer Res,2005,11(9):3184-3190.
[9] Koschmieder S,Halmos B,Levantini E,et al.Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol,2009,27(4):619-628.
[10] Pan Z,Zheng W,Zhang J,et al.Down-regulation of the expression of CCAAT/enhancer binding protein alpha gene in cervical squamous cell carcinoma. BMC Cancer,2014,14:417.
[11] Zhang S,Jiang T,Feng L,et al.Yin Yang-1 suppresses differentiation of hepatocellular carcinoma cells through the downreg-ulation of CCAAT/enhancer-binding protein alpha. J Mol Med (Berl),2012,90(9):1069-1077.
[12] Tseng H H,Hwang Y H,Yeh K T,et al.Reduced expression of C/EBP alpha protein in hepatocellular carcinoma is associated with advanced tumor stage and shortened patient survival. J Cancer Res Clin Oncol,2009,135(2):241-247.
[13] Hardiville S,Hart G W.Nutrient regulation of signaling,transcription,and cell physiology by O-GlcNAcylation. Cell Metab,2014,20(2):208-213.
[14] Love D C,Ghosh S,Mondoux M A,et al.Dynamic O-GlcNAc cycling at promoters of Caenorhabditis elegans genes regulating longevity,stress,and immunity. Proc Natl Acad Sci U S A,2010,107(16):7413-7418.
[15] Ma Z,Vosseller K.Cancer metabolism and elevated O-GlcNAc in oncogenic signaling. J Biol Chem,2014,289(50):34457-34465.[16] Xu W,Zhang X,Wu J L,et al. O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress. J Hepatol,2017,67(2):310-320.
[17] Zhu Q,Zhou L,Yang Z,et al.O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Med Oncol,2012,29(2):985-993.
[18] Lourenco A R,Coffer P J.A tumor suppressor role for C/EBPalpha in solid tumors:more than fat and blood. Oncogene,2017,36(37):5221-5230.
[19] Tseng H H,Hwang Y H,Yeh K T,et al.Reduced expression of C/EBP alpha protein in hepatocellular carcinoma is associated with advanced tumor stage and shortened patient survival. J Cancer Res Clin Oncol,2009,135(2):241-247.
[20] Tan E H,Hooi S C,Laban M,et al.CCAAT/enhancer binding protein alpha knock-in mice exhibit early liver glycogen storage and reduced susceptibility to hepatocellular carcinoma. Cancer Res,2005,65(22):10330-10337.
[21] Zhao X,Voutila J,Ghobrial S,et al.Treatment of Liver Cancer by C/EBPA saRNA. Adv Exp Med Biol,2017,983:189-194. |